Literature DB >> 26269189

The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.

Zaza M Ndhlovu1, Eleni Stampouloglou2, Kevin Cesa2, Orestes Mavrothalassitis2, Donna Marie Alvino2, Jonathan Z Li3, Shannon Wilton2, Daniel Karel2, Alicja Piechocka-Trocha2, Huabiao Chen4, Florencia Pereyra3, Bruce D Walker5.   

Abstract

UNLABELLED: Previous studies have shown that elite controllers with minimal effector T cell responses harbor a low-frequency, readily expandable, highly functional, and broadly directed memory population. Here, we interrogated the in vivo relevance of this cell population by investigating whether the breadth of expandable memory responses is associated with the magnitude of residual viremia in individuals achieving durable suppression of HIV infection. HIV-specific memory CD8(+) T cells were expanded by using autologous epitopic and variant peptides. Viral load was measured by an ultrasensitive single-copy PCR assay. Following expansion, controllers showed a greater increase in the overall breadth of Gag responses than did untreated progressors (P = 0.01) as well as treated progressors (P = 0.0003). Nef- and Env-specific memory cells expanded poorly for all groups, and their expanded breadths were indistinguishable among groups (P = 0.9 for Nef as determined by a Kruskal-Wallis test; P = 0.6 for Env as determined by a Kruskal-Wallis test). More importantly, we show that the breadth of expandable, previously undetectable Gag-specific responses was inversely correlated with residual viral load (r = -0.6; P = 0.009). Together, these data reveal a direct link between the abundance of Gag-specific expandable memory responses and prolonged maintenance of low-level viremia. Our studies highlight a CD8(+) T cell feature that would be desirable in a vaccine-induced T cell response. IMPORTANCE: Many studies have shown that the rare ability of some individuals to control HIV infection in the absence of antiretroviral therapy appears to be heavily dependent upon special HIV-specific killer T lymphocytes that are able to inhibit viral replication. The identification of key features of these immune cells has the potential to inform rational HIV vaccine design. This study shows that a special subset of killer lymphocytes, known as central memory CD8(+) T lymphocytes, is at least partially involved in the durable control of HIV replication. HIV controllers maintain a large proportion of Gag-specific expandable memory CD8(+) T cells involved in ongoing viral suppression. These data suggest that induction of this cell subset by future HIV vaccines may be important for narrowing possible routes of rapid escape from vaccine-induced CD8(+) T cell responses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26269189      PMCID: PMC4621138          DOI: 10.1128/JVI.01527-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Authors:  Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors
Journal:  Nat Immunol       Date:  2002-10-07       Impact factor: 25.606

2.  Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses.

Authors:  Zaza M Ndhlovu; Jacqueline Proudfoot; Kevin Cesa; Donna Marie Alvino; Ashley McMullen; Seanna Vine; Eleni Stampouloglou; Alicja Piechocka-Trocha; Bruce D Walker; Florencia Pereyra
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

3.  Evolution and transmission of stable CTL escape mutations in HIV infection.

Authors:  P J Goulder; C Brander; Y Tang; C Tremblay; R A Colbert; M M Addo; E S Rosenberg; T Nguyen; R Allen; A Trocha; M Altfeld; S He; M Bunce; R Funkhouser; S I Pelton; S K Burchett; K McIntosh; B T Korber; B D Walker
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

4.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

Review 5.  Timeline: AIDS pathogenesis: what have two decades of HIV research taught us?

Authors:  Sarah L Rowland-Jones
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

6.  Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.

Authors:  Bradley H Edwards; Anju Bansal; Steffanie Sabbaj; Janna Bakari; Mark J Mulligan; Paul A Goepfert
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

Authors:  Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

8.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

9.  Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

Authors:  M M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; David R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes.

Authors:  Ayub Ali; Rachel Lubong; Hwee Ng; David G Brooks; Jerome A Zack; Otto O Yang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  23 in total

1.  DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.

Authors:  Xintao Hu; Antonio Valentin; Frances Dayton; Viraj Kulkarni; Candido Alicea; Margherita Rosati; Bhabadeb Chowdhury; Rajeev Gautam; Kate E Broderick; Niranjan Y Sardesai; Malcolm A Martin; James I Mullins; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2016-10-12       Impact factor: 5.422

Review 2.  Reprint of: Virus-Specific T Cells: Broadening Applicability.

Authors:  A John Barrett; Susan Prockop; Catherine M Bollard
Journal:  Biol Blood Marrow Transplant       Date:  2018-03       Impact factor: 5.742

3.  Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors.

Authors:  David Shasha; Dan Karel; Olivia Angiuli; Adam Greenblatt; Musie Ghebremichael; Xu Yu; Filippos Porichis; Bruce D Walker
Journal:  J Leukoc Biol       Date:  2016-07-12       Impact factor: 4.962

Review 4.  Virus-Specific T Cells: Broadening Applicability.

Authors:  A John Barrett; Susan Prockop; Catherine M Bollard
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-12       Impact factor: 5.742

5.  In chronic infection, HIV gag-specific CD4+ T cell receptor diversity is higher than CD8+ T cell receptor diversity and is associated with less HIV quasispecies diversity.

Authors:  Mark A Pilkinton; Wyatt J McDonnell; Louise Barnett; Abha Chopra; Rama Gangula; Katie D White; Shay Leary; Jennifer Currenti; Silvana Gaudieri; Simon A Mallal; Spyros A Kalams
Journal:  J Virol       Date:  2021-02-03       Impact factor: 5.103

6.  Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers.

Authors:  Fatema Z Chowdhury; Zhengyu Ouyang; Maria Buzon; Bruce D Walker; Mathias Lichterfeld; Xu G Yu
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

7.  Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Authors:  Nicolas Noel; Ruth Peña; Annie David; Veronique Avettand-Fenoel; Itziar Erkizia; Esther Jimenez; Camille Lecuroux; Christine Rouzioux; Faroudy Boufassa; Gianfranco Pancino; Alain Venet; Carine Van Lint; Javier Martinez-Picado; Olivier Lambotte; Asier Sáez-Cirión; Julia G Prado
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 8.  T-cell therapies for HIV: Preclinical successes and current clinical strategies.

Authors:  Shabnum Patel; R Brad Jones; Douglas F Nixon; Catherine M Bollard
Journal:  Cytotherapy       Date:  2016-06-02       Impact factor: 5.414

9.  Subdominant Gag-specific anti-HIV efficacy in an HLA-B*57-positive elite controller.

Authors:  Ellen M Leitman; Christian B Willberg; Andrew De Burgh-Thomas; Hendrik Streeck; Philip J R Goulder; Philippa C Matthews
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

10.  Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.

Authors:  G Haidari; A Cope; A Miller; S Venables; C Yan; H Ridgers; K Reijonen; D Hannaman; A Spentzou; P Hayes; G Bouliotis; A Vogt; S Joseph; B Combadiere; S McCormack; R J Shattock
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.